ASX Health Stocks: Patrys to start Phase 1 trial as drug production process put in motion
Biotech Patrys has confirmed it is on schedule to test its cancer hunting and battling drug on human subjects, thanks to a manufacturing deal.
Biotech Patrys (ASX:PAB) has confirmed it is on schedule to test its cancer hunting and battling drug on human subjects, thanks to a manufacturing deal.
The therapeutic antibody development biotech’s contract manufacturing and development oganisation (CDMO) has confirmed that a manufacturing slot for the GMP (good manufacturing practice) production of PAT-DX1 will be available in Q1 of 2024.
For the latest real estate news, sign up here for free Stockhead daily newsletters
Patrys says it’s confident the drug material from this manufacturing run will enable the company to initiate its first-in-human clinical trial of PAT-DX1 in the second half of 2024, as previously guided.
In addition, Patrys confirmed that its GLP toxicology studies in both rats and non-human primates were complete, and that reports from them did not identify any safety or tolerability issues that might affect the proposed Phase 1 clinical trial of PAT-DX1.
“This manufacturing run is expected to produce the drug material that Patrys will use in the Phase 1 clinical trial of PAT-DX1 that is scheduled for the second half of calendar year 2024,” said Patrys’ CEO Dr James Campbell.
“With positive results from our final preclinical toxicology studies in hand, we look forward to reporting on the progress of manufacturing and other activities as we work towards initiating the clinical development of our deoxymab technology.”
MORE FROM STOCKHEAD: Island Pharma advances antiviral study | Global fitness sector pumping up companies | LTR Pharma could be next big thing
A promising cancer drug Patrys’ PAT-DX1 is a form of deoxymab, a chemical compound that is attracted to, and binds to, strands of DNA.
All tumours, regardless of what type of cancer or where it is located, release DNA into the bloodstream. Deoxymabs are attracted to this DNA, and consequently are able to locate both primary and secondary cancers (metastases) throughout the body.
This opens up the potential to use deoxymabs as pan-cancer seeking agents for the targeted delivery of cancer therapies.
Patrys’ PAT-DX1 has been shown to reduce tumour size.
Visit Stockhead, where ASX small caps are big deals
The drug is able to penetrate the semi-permeable membrane between the blood and the interstitium of the brain, making it more effective.
PAT-DX1 is also tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens.
The US Patent and Trademark Organisation (US PTO) has granted two patents that provide further intellectual property protection for Patrys’ deoxymab antibody technology until 2039.
There are now six granted patents covering the unconjugated form of deoxymab 3E10 (and derivatives thereof) in Europe, Japan, China, and three granted in the US.
At 3pm Wednesday (AEDT), Patrys’s share price was up nearly 7 per cent for the day.
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here
Investor Guide: Health & Biotech FY2025
In this special investor guide, health and biotech guru Tim Boreham leads Stockhead’s deep dive into the most cutting edge sector on the ASX.
Investor Guide: Gold & Copper FY2025
Stockhead's writers - including mining guru Barry FitzGerald - take you inside the copper and gold markets, and zero in on juniors exploring for the next major mine.